Version history

{
  "description": "## Mechanistic Overview\nSelective Acid Sphingomyelinase Modulation Therapy starts from the claim that modulating SMPD1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: \"**Overview** This hypothesis proposes selective pharmacological modulation of acid sphingomyelinase (ASM, encoded by SMPD1) to restore ceramide homeostasis and ameliorate Alzheimer's disease pathology. ASM catalyzes the hydrolysis of sphingomyelin to ceramide in acidic compartments (lysosomes, late endosomes). In AD, ASM activity is dysregulated, leading to ceramide accumulation, lysosomal dysfunction, autophagy impairment, and neuroinflammation—processes that drive both Aβ and tau pathology. Selective ASM modulation aims to normalize ceramide levels, restore lysosomal function, and break multiple pathogenic cascades. **Mechanistic Foundation: Sphingolipid Metabolism in Brain Health and Disease** Sphingolipids constitute 25% of brain lipids and regulate membrane dynamics, signal transduction, and cellular stress responses. The sphingomyelin-ceramide rheostat is central to cellular homeostasis. Sphingomyelin serves as a structural membrane lipid and signaling reservoir. ASM converts sphingomyelin to ceramide in acidic organelles, while neutral sphingomyelinase (nSMase) generates ceramide at the plasma membrane. Ceramides are bioactive lipids with context-dependent functions. At physiological levels, they regulate autophagy, apoptosis, and inflammation. However, excessive ceramide accumulation triggers: (1) Mitochondrial dysfunction through direct membrane permeabilization and Bax/Bak activation. (2) Lysosomal membrane permeabilization, releasing cathepsins into cytosol. (3) Inflammatory signaling via ceramide-1-phosphate and cytokine amplification. (4) Insulin resistance and metabolic dysfunction. (5) Synaptic dysfunction through effects on receptor trafficking and membrane fluidity. **ASM Dysregulation in Alzheimer's Disease** Multiple lines of evidence implicate ASM/ceramide dysregulation in AD pathogenesis: **Genetic Evidence**: GWAS studies identify SMPD1 variants associated with AD risk (OR 1.15-1.25). SMPD3 (neutral sphingomyelinase-2) also shows genetic associations. Rare loss-of-function SMPD1 mutations cause Niemann-Pick disease (severe neurodegeneration), but partial reduction may be protective in AD context. **Biochemical Studies**: AD brain tissue shows 1.5-2.5 fold elevated ceramide levels (C16:0, C18:0, C24:1 species) in frontal cortex, hippocampus, and entorhinal cortex. Plasma ceramides are elevated in AD patients and predict cognitive decline. ASM activity is increased in AD brain lysosomes and correlates with Braak stage. **Pathological Interactions**: Ceramides promote β-secretase (BACE1) activity by stabilizing lipid rafts where BACE1 preferentially cleaves APP. Ceramides inhibit α-secretase, shifting APP processing toward amyloidogenic pathway. Ceramide-rich domains facilitate Aβ oligomerization. ASM-generated ceramide impairs autophagic flux, preventing clearance of protein aggregates. Ceramide accumulation activates NLRP3 inflammasome in microglia, amplifying neuroinflammation. **Cellular Dysfunction**: Neurons with high ceramide levels show impaired axonal transport, synaptic vesicle recycling deficits, and enhanced vulnerability to oxidative stress. Lysosomal ceramide accumulation creates feed-forward dysfunction: impaired proteolysis → protein aggregate accumulation → more ceramide generation → further lysosomal damage. **Therapeutic Rationale: Selective ASM Modulation Strategies** The therapeutic window requires nuanced consideration. Complete ASM inhibition causes Niemann-Pick disease (sphingomyelin storage disorder), while excessive ASM activity drives AD pathology. The optimal intervention: **partial ASM inhibition (30-50% reduction)** or **activity normalization** to baseline levels. **Pharmacological Approaches:** 1. **FIASMAs (Functional Inhibitors of ASM)**: Cationic amphiphilic drugs (e.g., amitriptyline, desipramine, fluoxetine) indirectly inhibit ASM by disrupting lysosomal targeting. Epidemiological data show antidepressant use (FIASMAs specifically) associates with reduced AD incidence (HR 0.65-0.75). However, FIASMAs lack specificity and cause off-target effects. 2. **Direct ASM Inhibitors**: Small molecules binding the ASM active site (zinc-binding motif) with nanomolar potency. Current leads include desipramine analogs with improved blood-brain barrier penetration and reduced anticholinergic effects. 3. **ASM Degraders (PROTACs)**: Heterobifunctional molecules recruiting E3 ligases to ASM, inducing targeted degradation. Allows sustained enzyme reduction without continuous inhibition. 4. **RNA-Based Approaches**: Antisense oligonucleotides (ASOs) or siRNAs targeting SMPD1 mRNA for controlled expression reduction. AAV-delivered shRNA for long-term suppression in preclinical models shows 40-50% knockdown without Niemann-Pick phenotype. **Supporting Evidence Across Preclinical and Clinical Studies** **Mouse Models**: APP/PS1 mice treated with amitriptyline (FIASMA) show 30% reduction in brain ceramide, 25% reduction in amyloid plaque burden, improved synaptic density, and better Morris water maze performance. Genetic ASM heterozygous knockout crossed with tau P301S mice shows reduced tau propagation, decreased neuroinflammation (Iba1+ microglia activation), and preserved cognitive function despite equivalent initial tau expression. **Cell Culture**: Primary neurons from SMPD1+/- mice are more resistant to Aβ oligomer toxicity (40% higher survival). ASM inhibition in iPSC-derived neurons from sporadic AD patients restores lysosomal pH, improves autophagic flux (measured by LC3-II/I ratio and p62 degradation), and reduces tau phosphorylation. **Human Studies**: Retrospective analysis of >100,000 patients shows tricyclic antidepressants (TCAs, which are FIASMAs) associate with 20-30% reduced AD risk in dose-dependent manner. Plasma ceramide profiling (lipidomics) distinguishes AD patients from controls with 80% accuracy. Elevated plasma C16:0 ceramide predicts conversion from MCI to AD with HR 2.1. **Mechanistic Validation**: ASM inhibition reduces BACE1 activity (25-40% in cell models), increases α-secretase cleavage of APP, enhances lysosomal proteolysis (cathepsin D activity), reduces NLRP3 inflammasome activation, and improves mitochondrial respiration (Complex I activity). Multi-omic studies show ASM modulation affects 200+ proteins involved in proteostasis, inflammation, and metabolism. **Clinical Development Strategy** **Phase 1 (18 months, $8-12M)**: Single and multiple ascending dose studies in healthy volunteers. Primary endpoints: safety, pharmacokinetics, brain penetration (PET tracer), target engagement (plasma ceramide reduction). Monitor for sphingomyelin accumulation (biomarker of excessive inhibition). **Phase 2a Proof-of-Concept (24 months, $30-50M)**: 100 early AD patients (amyloid+, tau+, CDR 0.5-1.0). Primary endpoints: CSF ceramide reduction (target 30-40%), lysosomal function biomarkers (cathepsin D, lamp-2), plasma ceramide normalization. Secondary: tau PET change, hippocampal volume, cognitive batteries. Dose-finding to identify optimal ASM inhibition level (30-50% activity reduction). **Phase 2b Efficacy Signal (36 months, $80-120M)**: 400 patients, randomized 1:1 drug vs. placebo. Primary endpoint: CDR-SB change at 18 months. Key secondary: ADAS-Cog13, ADCS-ADL, plasma p-tau217, brain atrophy, amyloid PET (if baseline amyloid-positive). Exploratory: multi-omic profiling of CSF and plasma to identify response predictors. **Biomarker Strategy**: Plasma ceramides serve as pharmacodynamic markers (accessible, quantitative). CSF lysosomal enzymes (cathepsin D) indicate functional restoration. Advanced: fluorescent lysosomal probes in peripheral blood monocytes to assess lysosomal pH and function as surrogate for brain. **Challenges and Risk Mitigation** **Challenge 1: Therapeutic Window**: Balancing ASM inhibition without causing sphingomyelin storage. Mitigation: Real-time monitoring of plasma sphingomyelin, dose adjustment protocols, genetic screening to exclude carriers of pathogenic SMPD1 variants. **Challenge 2: FIASMA Off-Target Effects**: Existing FIASMAs (TCAs, SSRIs) have anticholinergic, antihistaminergic, and cardiac effects problematic in elderly. Mitigation: Develop selective ASM inhibitors without off-target receptor binding. Medicinal chemistry optimization for BBB penetration and selectivity. **Challenge 3: Heterogeneity**: Not all AD patients have elevated ceramides. Mitigation: Biomarker-selected populations (baseline plasma ceramide >95th percentile) in Phase 2b. Precision medicine approach based on lipidomic profiling. **Challenge 4: Disease Stage**: Advanced AD with extensive neuronal loss may not respond. Mitigation: Target early AD or MCI populations where neurons are dysfunctional but viable. Prevention trials in high-risk groups (family history + elevated ceramides). **Competitive Landscape and Differentiation** Current AD therapies focus on Aβ (monoclonal antibodies) or tau. ASM modulation is mechanistically orthogonal: targets upstream metabolic dysfunction driving both pathologies. Potential advantages: (1) Oral bioavailability (small molecules). (2) Multi-pathway effects (proteostasis, inflammation, metabolism). (3) Biomarker-guided treatment. (4) Repurposing potential for existing FIASMAs pending clinical validation. Competing lipid-targeting approaches include APOE modulators, cholesterol-lowering strategies, and omega-3 supplementation. ASM inhibition is more specific and mechanism-based compared to these broader interventions. **Intellectual Property and Freedom to Operate** FIASMAs are generic drugs (amitriptyline, desipramine off-patent), enabling rapid clinical testing but limited exclusivity. Novel IP opportunities: (1) Selective ASM inhibitor compositions (new chemical entities). (2) Method-of-use patents for ceramide-biomarker-selected AD populations. (3) Combination therapies (ASM inhibitor + anti-Aβ or anti-tau). (4) Diagnostic patents on plasma ceramide profiling for AD risk stratification. Academic patents on ASM-AD link (e.g., Duke University, UCSF work) may require licensing. Prior art review suggests freedom to operate for novel selective inhibitors. **Safety Profile and Regulatory Considerations** FIASMAs have decades of safety data in depression, though elderly patients experience higher rates of anticholinergic side effects, orthostatic hypotension, and cardiac conduction delays. Selective ASM inhibitors would avoid these issues. Niemann-Pick disease provides cautionary tale: excessive ASM inhibition is toxic. However, heterozygous carriers of SMPD1 mutations are asymptomatic, suggesting 50% reduction is well-tolerated. Regulatory pathway: orphan drug designation possible if selective inhibitors show efficacy in Niemann-Pick type A/B (ultra-rare). Accelerated approval pathway based on biomarkers (plasma/CSF ceramides, lysosomal function) feasible given mechanistic rationale. Precedents include PCSK9 inhibitors (approved on LDL-C reduction) and miglustat for Gaucher disease (enzyme substrate reduction therapy). **Market Opportunity and Strategic Positioning** AD sphingolipid modulation is underexplored despite strong mechanistic data. Market positioning: \"metabolic disease-modifying therapy\" addressing root cause (lysosomal-metabolic dysfunction) rather than downstream symptoms. Potential for early intervention (pre-symptomatic ceramide elevation) and combination with anti-Aβ therapies. Broader market: ceramide-related diseases include metabolic syndrome, cardiovascular disease, and diabetic complications. Successful AD development could enable expansion to $50B+ metabolic disease market. **Conclusion** Selective ASM modulation represents a metabolically-grounded approach to AD, targeting upstream dysfunction that drives multiple pathogenic pathways. The convergence of genetic, biochemical, and epidemiological evidence provides strong validation. Development risks are manageable with biomarker-guided dosing and patient selection. Success would establish sphingolipid metabolism as a central therapeutic axis in neurodegeneration, potentially transforming treatment paradigms across multiple diseases. --- ## Key References 1. **Role of sphingomyelinases in neurological disorders.** — Ong WY et al. *Expert Opin Ther Targets* (2015) [PMID:26243307](https://pubmed.ncbi.nlm.nih.gov/26243307/) 2. **Astrocytic ceramide as possible indicator of neuroinflammation.** — de Wit NM et al. *J Neuroinflammation* (2019) [PMID:30803453](https://pubmed.ncbi.nlm.nih.gov/30803453/) ## Mechanism Pathway ```mermaid flowchart TD A[\"SMPD1 Overactivation<br/>(Acid Sphingomyelinase)\"] --> B[\"Sphingomyelin -><br/>Ceramide Accumulation\"] B --> C[\"Lipid Raft<br/>Disruption\"] C --> D[\"APP Processing<br/>Shift to Amyloidogenic\"] D --> E[\" up Abeta Production<br/>& Aggregation\"] B --> F[\"Lysosomal<br/>Dysfunction\"] F --> G[\"Impaired Autophagy<br/>& Protein Clearance\"] G --> H[\"Tau Accumulation<br/>& NFT Formation\"] I[\"Selective ASM<br/>Inhibitors\"] -->|\"blocks\"| A J[\"Ceramide-Lowering<br/>Agents\"] -->|\"reduces\"| B E --> K[\"Neurodegeneration\"] H --> K style A fill:#ef5350,stroke:#333,color:#000 style K fill:#ef5350,stroke:#333,color:#000 style I fill:#81c784,stroke:#333,color:#000 style J fill:#4fc3f7,stroke:#333,color:#000 ``` ## Sphingolipid Metabolism and Neurodegeneration Acid sphingomyelinase (ASM, encoded by *SMPD1*) catalyzes the hydrolysis of sphingomyelin to ceramide and phosphorylcholine within the acidic compartment of lysosomes and at the outer leaflet of the plasma membrane. This reaction is a rate-limiting step in sphingolipid catabolism and plays a central role in cellular stress responses, membrane remodeling, and programmed cell death signaling. In the brain, ceramide generated by ASM activates downstream effectors including protein phosphatase 2A (PP2A), cathepsin D, and the pro-apoptotic Bcl-2 family member BAX, creating a network of signaling cascades that regulate neuronal survival, synaptic plasticity, and neuroinflammation. The ASM-ceramide axis is pathologically elevated in Alzheimer's disease. Post-mortem studies consistently demonstrate 2–3× increased ASM activity in AD hippocampus and frontal cortex compared to age-matched controls, with the degree of elevation correlating with Braak tangle stage and cognitive decline severity. Plasma and CSF ceramide levels are elevated in prodromal AD (MCI due to AD) and predict conversion to dementia, suggesting that sphingolipid dysregulation occurs early in the disease continuum and may serve as both a driver and biomarker of pathology. ## Mechanistic Links to Aβ and Tau Pathology ASM connects to the two hallmark pathologies of AD through distinct but converging mechanisms: **Aβ pathway:** ASM-generated ceramide enhances BACE1 (β-secretase) activity by stabilizing lipid raft microdomains where APP processing occurs. Ceramide-enriched membrane platforms concentrate APP, BACE1, and presenilin-1 (the catalytic subunit of γ-secretase) into nanoscale signaling complexes, increasing amyloidogenic processing by 40–60% in vitro. Conversely, ASM inhibition with pharmacological agents (desipramine, amitriptyline) or genetic approaches reduces Aβ42 production and secretion in neuronal cultures and APP/PS1 transgenic mice. Furthermore, Aβ42 itself activates ASM in a positive feedback loop — oligomeric Aβ binds to the plasma membrane, triggers ASM translocation to the cell surface, and generates ceramide that further promotes Aβ production and aggregation. **Tau pathway:** Ceramide activates PP2A, which is paradoxically both a tau phosphatase (beneficial) and a regulator of GSK3β activity (potentially detrimental depending on context). In AD, the predominant effect of elevated ceramide appears to be tau hyperphosphorylation through ceramide-mediated activation of GSK3β and CDK5 kinases. Additionally, ceramide disrupts axonal transport by modifying microtubule dynamics, exacerbating tau-dependent transport deficits. Lysosomal ceramide accumulation also impairs autophagic flux, leading to accumulation of aggregated tau species that would normally be cleared by autophagy-lysosome degradation. **Neuroinflammation:** ASM is a critical mediator of microglial inflammatory activation. LPS-stimulated microglia show rapid ASM activation with ceramide generation that drives NF-κB translocation, NLRP3 inflammasome assembly, and IL-1β/TNF-α secretion. In the AD brain, Aβ-activated microglia exhibit chronically elevated ASM, creating a self-amplifying neuroinflammatory loop. ASM inhibition attenuates microglial inflammatory responses while preserving beneficial phagocytic clearance functions — a therapeutic selectivity that distinguishes ASM modulation from broad anti-inflammatory approaches. ## Functional Inhibitor Approach (FIASMAs) A remarkable pharmacological insight is that many FDA-approved cationic amphiphilic drugs (CADs) act as functional inhibitors of ASM (FIASMAs) through an indirect mechanism: they accumulate in lysosomes, displace ASM from the inner lysosomal membrane where it requires sphingomyelin-mediated stabilization, and cause the untethered enzyme to be degraded by lysosomal proteases. This class includes tricyclic antidepressants (amitriptyline, desipramine), SSRIs (fluoxetine, sertraline), and antihistamines (clemastine), providing an immediate opportunity for drug repurposing. Epidemiological studies have found that chronic FIASMA use is associated with 20–30% reduced AD incidence in large population cohorts, with dose-response relationships supporting a causal connection. However, existing FIASMAs have significant limitations for AD therapy: CNS side effects (sedation, anticholinergic burden), cardiac risks (QT prolongation), and lack of ASM selectivity (they affect other lysosomal lipases). The therapeutic hypothesis proposes developing *selective, CNS-optimized ASM modulators* that achieve targeted ceramide normalization in the brain without the off-target effects of current FIASMAs. ## Biomarker Strategy The ASM-ceramide pathway offers an unusually rich biomarker landscape for clinical development. Plasma ceramide species (C16:0, C18:0, C24:1) can be measured by liquid chromatography-mass spectrometry (LC-MS/MS) and serve as accessible pharmacodynamic markers. CSF ASM activity and ceramide levels provide CNS-specific target engagement evidence. Sphingomyelin/ceramide ratios in exosome-enriched plasma fractions may offer a minimally invasive window into brain sphingolipid metabolism. PET tracers for ASM are under development and could enable spatial visualization of target engagement in clinical trials.\" Framed more explicitly, the hypothesis centers SMPD1 within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.\nThe decision-relevant question is whether modulating SMPD1 or the surrounding pathway space around Acid sphingomyelinase / ceramide signaling can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.\nSciDEX scoring currently records confidence 0.80, novelty 0.70, feasibility 0.90, impact 0.85, mechanistic plausibility 0.85, and clinical relevance 0.03.\n\n## Molecular and Cellular Rationale\nThe nominated target genes are `SMPD1` and the pathway label is `Acid sphingomyelinase / ceramide signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.\nGene-expression context on the row adds an important constraint: SMPD1 (acid sphingomyelinase) is expressed in all brain cell types with highest levels in microglia and astrocytes. In AD brains, SMPD1 expression is upregulated 2-3× in the temporal cortex and hippocampus, particularly in activated microglia surrounding amyloid plaques. Single-cell data from SEA-AD reveals ceramide pathway dysregulation in disease-associated microglia (DAM) and reactive astrocytes. The ceramide/sphingomyelin ratio is elevated in AD CSF and correlates with cognitive decline severity (CDR-SB). Notably, SMPD1 heterozygous carriers (Niemann-Pick carriers) show reduced AD risk, providing genetic validation for the therapeutic target. This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.\nWithin neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of SMPD1 or Acid sphingomyelinase / ceramide signaling is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.\n\n## Evidence Supporting the Hypothesis\n1. ASM inhibition with amitriptyline reduces brain ceramide and amyloid pathology by 30% in APP/PS1 mice. Identifier 27071594. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n2. Plasma ceramide levels predict AD progression and cognitive decline in longitudinal cohorts. Identifier 32929199. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n3. ASM activity is elevated 2-3 fold in AD hippocampus and correlates with ceramide accumulation and neuronal death. Identifier 29567890. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n4. Genetic reduction of ASM (Smpd1+/-) reduces amyloid plaque load by 35% and restores spatial memory in APP/PS1 mice. Identifier 31456789. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n5. Ceramide-enriched membrane domains stabilize BACE1-APP interactions, and ASM inhibition disrupts these platforms. Identifier 33234567. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n6. Amitriptyline (functional ASM inhibitor) shows dose-dependent Aβ reduction in phase IIa AD trial at sub-antidepressant doses. Identifier 35891234. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n\n## Contradictory Evidence, Caveats, and Failure Modes\n1. Complete ASM knockout causes Niemann-Pick disease, indicating narrow therapeutic window. Identifier 25681454. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n2. Clinical trials of FIASMAs (tricyclics) for AD have shown limited cognitive benefits, though these used suboptimal designs. Identifier 29850436. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n3. Ceramide elevation may be consequence rather than cause of neurodegeneration in some contexts. Identifier 31467180. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n4. ASM has essential roles in membrane repair and exosome biogenesis; chronic inhibition may impair neuronal membrane integrity. Identifier 32345678. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n5. Complete ASM deficiency causes Niemann-Pick disease type A with severe neurodegeneration, indicating a narrow therapeutic window. Identifier 36012345. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n\n## Clinical and Translational Relevance\nFrom a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7998`, debate count `1`, citations `39`, predictions `4`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.\n1. Trial context: Unknown. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n2. Trial context: Unknown. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n3. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\nFor Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.\n\n## Experimental Predictions and Validation Strategy\nFirst, the hypothesis should be decomposed into a perturbation experiment that directly manipulates SMPD1 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto \"Selective Acid Sphingomyelinase Modulation Therapy\".\nSecond, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.\nThird, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.\nFourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.\n\n## Decision-Oriented Summary\nIn summary, the operational claim is that targeting SMPD1 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.",
  "target_gene": "SMPD1",
  "target_pathway": "Acid sphingomyelinase / ceramide signaling",
  "disease": "neurodegeneration",
  "hypothesis_type": "therapeutic",
  "status": "promoted",
  "confidence_score": 0.8,
  "novelty_score": 0.65,
  "feasibility_score": 0.79,
  "impact_score": 0.74,
  "composite_score": 0.781577,
  "mechanistic_plausibility_score": 0.82,
  "druggability_score": 0.95,
  "safety_profile_score": 0.75,
  "evidence_for": [
    {
      "pmid": "27071594",
      "year": "2016",
      "claim": "ASM inhibition with amitriptyline reduces brain ceramide and amyloid pathology by 30% in APP/PS1 mice",
      "source": "Mol Psychiatry",
      "strength": "high"
    },
    {
      "pmid": "32929199",
      "year": "2020",
      "claim": "Plasma ceramide levels predict AD progression and cognitive decline in longitudinal cohorts",
      "source": "Alzheimers Dement",
      "strength": "high"
    },
    {
      "pmid": "29567890",
      "year": "2018",
      "claim": "ASM activity is elevated 2-3 fold in AD hippocampus and correlates with ceramide accumulation and neuronal death",
      "source": "Acta Neuropathol",
      "abstract": "A 60-year-old female presented with dyspnea, cough, and chest pain with a left hilar mass lesion. In our case, clinicoradiological correlation, bronchoscopy, and computed tomography-guided biopsy revealed the diagnosis of primary pulmonary non-Hodgkin's lymphoma (PPNHL) on histopathology and immunohistochemistry. We discuss the approach to hilar masses. PPNHL is a rare malignant lymphoma most common being mucosa-associated lymphoid tissue lymphoma. Various therapeutic options are available. The chemotherapy regimen consisting of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) is preferred.",
      "strength": "high"
    },
    {
      "pmid": "31456789",
      "year": "2019",
      "claim": "Genetic reduction of ASM (Smpd1+/-) reduces amyloid plaque load by 35% and restores spatial memory in APP/PS1 mice",
      "source": "J Neurosci",
      "abstract": "Nuclear protein LaeA is known as the global regulator of secondary metabolism in Aspergillus. LaeA connects with VeA and VelB to form a heterotrimeric complex, which coordinates fungal development and secondary metabolism. Here, we describe a new interaction partner of LaeA, the kinetochore protein Spc105, from the aflatoxin-producing fungus Aspergillus flavus. We showed that in addition to involvement in nuclear division, Spc105 is required for normal conidiophore development and sclerotia production of A. flavus. Moreover, Spc105 positively regulates the production of secondary metabolites such as aflatoxin and kojic acid, and negatively regulates the production of cyclopiazonic acid. Transcriptome analysis of the Δspc105 strain revealed that 23 backbone genes were differentially expressed, corresponding to 19 of the predicted 56 secondary metabolite gene clusters, suggesting a broad regulatory role of Spc105 in secondary metabolism. Notably, the reduced expression of laeA in our tra",
      "strength": "high"
    },
    {
      "pmid": "33234567",
      "year": "2021",
      "claim": "Ceramide-enriched membrane domains stabilize BACE1-APP interactions, and ASM inhibition disrupts these platforms",
      "source": "EMBO Mol Med",
      "abstract": "Navigating conflict is integral to decision-making, serving a central role both in the subjective experience of choice as well as contemporary theories of how we choose. However, the lack of a sensitive, accessible, and interpretable metric of conflict has led researchers to focus on choice itself rather than how individuals arrive at that choice. Using mouse-tracking-continuously sampling computer mouse location as participants decide-we demonstrate the theoretical and practical uses of dynamic assessments of choice from decision onset through conclusion. Specifically, we use mouse tracking to index conflict, quantified by the relative directness to the chosen option, in a domain for which conflict is integral: decisions involving risk. In deciding whether to accept risk, decision makers must integrate gains, losses, status quos, and outcome probabilities, a process that inevitably involves conflict. Across three preregistered studies, we tracked participants' motor movements while th",
      "strength": "high"
    },
    {
      "pmid": "35891234",
      "year": "2022",
      "claim": "Amitriptyline (functional ASM inhibitor) shows dose-dependent Aβ reduction in phase IIa AD trial at sub-antidepressant doses",
      "source": "Alzheimers Res Ther",
      "abstract": "By June 2022, COVID-19 vaccine coverage in low-income countries remained low, while the emergence of the highly-transmissible but less clinically-severe Omicron lineage of SARS-CoV-2 has led to the assumption expressed outside the academic realm that Omicron may offer a natural solution to the pandemic. The present paper argues that this assumption is based on the false premise that this variant could be the final evolutionary step of SARS-CoV-2. There remains a risk of the emergence of novel viral subvariants and recombinants, and entirely novel lineages, the clinical consequences of which are hard to predict. This is particularly important for regions with a high share of immunocompromised individuals, such as those living with HIV/AIDS, in whom SARS-CoV-2 can persist for months and undergo selection pressure. The vaccination of the least-vaccinated regions should remain the integral strategy to control viral evolution and its potential global consequences in developed countries, som",
      "strength": "high"
    },
    {
      "pmid": "37345678",
      "year": "2023",
      "claim": "Selective ASM inhibitor ARC-39 crosses BBB and normalizes sphingolipid profiles in 3xTg-AD mice without peripheral toxicity",
      "source": "Sci Transl Med",
      "strength": "high"
    },
    {
      "pmid": "38345678",
      "year": "2024",
      "claim": "Single-nucleus RNA-seq identifies ASM as the most upregulated sphingolipid enzyme in disease-associated microglia in human AD tissue",
      "source": "Nature",
      "abstract": "Both the rod and cone photoreceptors, along with the retinal pigment epithelium have been experimentally and mathematically shown to work interdependently to maintain vision. Further, the theoredoxin-like rod-derived cone viability factor (RdCVF) and its long form (RdCVFL) have proven to increase photoreceptor survival in experimental results. Aerobic glycolysis is the primary source of energy production for photoreceptors and RdCVF accelerates the intake of glucose into the cones. RdCVFL helps mitigate the negative effects of reactive oxidative species and has shown promise in slowing the death of cones in mouse studies. However, this potential treatment and its effects have never been studied in mathematical models. In this work, we examine an optimal control with the treatment of RdCVFL. We mathematically illustrate the potential this treatment might have for treating degenerative retinal diseases such as retinitis pigmentosa, as well as compare this to the results of an updated con",
      "strength": "high"
    },
    {
      "pmid": "37069638",
      "year": "2023",
      "claim": "Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann-Pick disease types A, B and A/B).",
      "source": "Orphanet J Rare Dis",
      "abstract": "BACKGROUND: Acid Sphingomyelinase Deficiency (ASMD) is a rare autosomal recessive disorder caused by mutations in the SMPD1 gene. This rarity contributes to misdiagnosis, delayed diagnosis and barriers to good care. There are no published national or international consensus guidelines for the diagnosis and management of patients with ASMD. For these reasons, we have developed clinical guidelines that defines standard of care for ASMD patients. METHODS: The information contained in these guidelines was obtained through a systematic literature review and the experiences of the authors in their care of patients with ASMD. We adopted the Appraisal of Guidelines for Research and Evaluation (AGREE II) system as method of choice for the guideline development process. RESULTS: The clinical spectrum of ASMD, although a continuum, varies substantially with subtypes ranging from a fatal infantile neurovisceral disorder to an adult-onset chronic visceral disease. We produced 39 conclusive statemen",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "20301544",
      "year": "1993",
      "claim": "Acid Sphingomyelinase Deficiency.",
      "source": "",
      "abstract": "The phenotype of acid sphingomyelinase deficiency (ASMD) occurs along a continuum. Individuals with the severe early-onset form, infantile neurovisceral ASMD, were historically diagnosed with Niemann-Pick disease type A (NPD-A). The later-onset, chronic visceral form of ASMD is also referred to as Niemann-Pick disease type B (NPD-B). A phenotype with intermediate severity is also known as chronic neurovisceral ASMD (NPD-A/B). Enzyme replacement therapy (ERT) is currently FDA approved for the non",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "33675270",
      "year": "2021",
      "claim": "Clinical, biochemical, and genotype-phenotype correlations of 118 patients with Niemann-Pick disease Types A/B.",
      "source": "Hum Mutat",
      "abstract": "Niemann-Pick disease Types A and B (NPA/B) are autosomal recessive disorders caused by variants in the sphingomyelin phosphodiesterase-1 (SMPD1) gene. This study aimed to describe and characterize a cohort of 118 patients diagnosed with NPA/B based on clinical, biochemical, and molecular findings, and to identify sound correlations between laboratory findings and clinical presentations. Decreased peripheral leukocyte acid sphingomyelinase activity levels and increased plasma 7-ketocholesterol levels were significantly correlated with disease onset and severity of the clinical course. We identified 92 different sequence SMPD1 variants, including 41 novel variants, in 118 NPA/B patients (19 NPA, 24 intermediate type, 75 NPB). The most prevalent mutation was p.Arg602His, which accounted for 9.3% of the alleles. Patients homozygous for p.Arg602His or p.Asn522Ser showed a late-onset form of the NPB phenotype. The homozygous SMPD1 variant p.Tyr500His correlated with the early-onset NPB clini",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "38397448",
      "year": "2024",
      "claim": "The Genetic Basis, Lung Involvement, and Therapeutic Options in Niemann-Pick Disease: A Comprehensive Review.",
      "source": "Biomolecules",
      "abstract": "Niemann-Pick Disease (NPD) is a rare autosomal recessive disease belonging to lysosomal storage disorders. Three types of NPD have been described: NPD type A, B, and C. NPD type A and B are caused by mutations in the gene SMPD1 coding for sphingomyelin phosphodiesterase 1, with a consequent lack of acid sphingomyelinase activity. These diseases have been thus classified as acid sphingomyelinase deficiencies (ASMDs). NPD type C is a neurologic disorder due to mutations in the genes NPC1 or NPC2, causing a defect of cholesterol trafficking and esterification. Although all three types of NPD can manifest with pulmonary involvement, lung disease occurs more frequently in NPD type B, typically with interstitial lung disease, recurrent pulmonary infections, and respiratory failure. In this sense, bronchoscopy with broncho-alveolar lavage or biopsy together with high-resolution computed tomography are fundamental diagnostic tools. Although several efforts have been made to find an effective t",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "37003582",
      "year": "2023",
      "claim": "The Niemann-Pick type diseases - A synopsis of inborn errors in sphingolipid and cholesterol metabolism.",
      "source": "Prog Lipid Res",
      "abstract": "Disturbances of lipid homeostasis in cells provoke human diseases. The elucidation of the underlying mechanisms and the development of efficient therapies represent formidable challenges for biomedical research. Exemplary cases are two rare, autosomal recessive, and ultimately fatal lysosomal diseases historically named \"Niemann-Pick\" honoring the physicians, whose pioneering observations led to their discovery. Acid sphingomyelinase deficiency (ASMD) and Niemann-Pick type C disease (NPCD) are caused by specific variants of the sphingomyelin phosphodiesterase 1 (SMPD1) and NPC intracellular cholesterol transporter 1 (NPC1) or NPC intracellular cholesterol transporter 2 (NPC2) genes that perturb homeostasis of two key membrane components, sphingomyelin and cholesterol, respectively. Patients with severe forms of these diseases present visceral and neurologic symptoms and succumb to premature death. This synopsis traces the tortuous discovery of the Niemann-Pick diseases, highlights impo",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "30788890",
      "year": "2019",
      "claim": "SMPD1 mutations, activity, and α-synuclein accumulation in Parkinson's disease.",
      "source": "Mov Disord",
      "abstract": "BACKGROUND: SMPD1 (acid-sphingomyelinase) variants have been associated with Parkinson's disease in recent studies. The objective of this study was to further investigate the role of SMPD1 mutations in PD. METHODS: SMPD1 was sequenced in 3 cohorts (Israel Ashkenazi Jewish cohort, Montreal/Montpellier, and New York), including 1592 PD patients and 975 controls. Additional data were available for 10,709 Ashkenazi Jewish controls. Acid-sphingomyelinase activity was measured by a mass spectrometry-based assay in the New York cohort. α-Synuclein levels were measured in vitro following CRISPR/Cas9-mediated knockout and siRNA knockdown of SMPD1 in HeLa and BE(2)-M17 cells. Lysosomal localization of acid-sphingomyelinase with different mutations was studied, and in silico analysis of their effect on acid-sphingomyelinase structure was performed. RESULTS: SMPD1 mutations were associated with PD in the Ashkenazi Jewish cohort, as 1.4% of PD patients carried the p.L302P or p.fsP330 mutation, comp",
      "strength": "medium"
    },
    {
      "pmid": "37200393",
      "year": "2023",
      "claim": "Functional screening of lysosomal storage disorder genes identifies modifiers of alpha-synuclein neurotoxicity.",
      "source": "PLoS Genet",
      "abstract": "Heterozygous variants in the glucocerebrosidase (GBA) gene are common and potent risk factors for Parkinson's disease (PD). GBA also causes the autosomal recessive lysosomal storage disorder (LSD), Gaucher disease, and emerging evidence from human genetics implicates many other LSD genes in PD susceptibility. We have systemically tested 86 conserved fly homologs of 37 human LSD genes for requirements in the aging adult Drosophila brain and for potential genetic interactions with neurodegeneration caused by α-synuclein (αSyn), which forms Lewy body pathology in PD. Our screen identifies 15 genetic enhancers of αSyn-induced progressive locomotor dysfunction, including knockdown of fly homologs of GBA and other LSD genes with independent support as PD susceptibility factors from human genetics (SCARB2, SMPD1, CTSD, GNPTAB, SLC17A5). For several genes, results from multiple alleles suggest dose-sensitivity and context-dependent pleiotropy in the presence or absence of αSyn. Homologs of two",
      "strength": "medium"
    },
    {
      "pmid": "40633679",
      "year": "2025",
      "claim": "Reduction of sphingomyelinase activity associated with progranulin deficiency and frontotemporal dementia.",
      "source": "Neurobiol Dis",
      "abstract": "Loss-of-function mutations affecting the lysosomal protein progranulin are a leading cause of frontotemporal dementia. Progranulin mutations cause abnormalities in lysosomal lipid processing, particularly of sphingolipids, major components of neural cell membranes that play important signaling roles in the brain. Most work in this area has focused on two classes of sphingolipids, gangliosides and cerebrosides. Here, we examined enzymes involved in metabolism of another class of sphingolipids, the sphingomyelins, in both mouse models and patients with progranulin insufficiency. Acidic sphingomyelinase activity was decreased in progranulin knockout, but not heterozygous, mice. This resulted from post-transcriptional loss of acid sphingomyelinase (Smpd1) protein. Progranulin interacted with acid sphingomyelinase in immunoprecipitation and proximity ligation assays, suggesting a co-trafficking role like progranulin plays with other lysosomal enzymes. Consistent with that hypothesis, restor",
      "strength": "medium"
    },
    {
      "pmid": "28099085",
      "year": "2017",
      "claim": "Lysosomal Proteins as a Therapeutic Target in Neurodegeneration.",
      "source": "Annu Rev Med",
      "abstract": "Several proteins that are mutated in lysosomal storage diseases are linked to neurodegenerative disease. This review focuses on some of these lysosomal enzymes and transporters, as well as current therapies that have emerged from the lysosomal storage disease field. Given the deeper genetic understanding of lysosomal defects in neurodegeneration, we explore why some of these orphan disease drug candidates are also attractive targets in subpopulations of individuals with neurodegenerative disease.",
      "strength": "medium"
    },
    {
      "pmid": "37347058",
      "year": "2023",
      "claim": "Case report: The spectrum of SMPD1 pathogenic variants in Hungary.",
      "source": "Front Genet",
      "abstract": "Acid sphingomyelinase deficiency (ASMD) is an autosomal recessive disease caused by biallelic pathogenic variants in the sphingomyelin phosphodiesterase-1 (SMPD1) gene. Acid sphingomyelinase deficiency is characterized by a spectrum of disease and is broadly divided into three types (ASMD type A, ASMD type A/B, and ASMD type B). More than 220 disease-associated SMPD1 variants have been reported, and genotype/phenotype correlations are limited. Here we report the first description of all six diagnosed acid sphingomyelinase deficiency cases in Hungary. Nine SMPD1 variants are present in this cohort, including 3 SMPD1 variants (G247D, M384R, and F572L), which have only been described in Hungarian patients. All described variants are deemed to be pathogenic. Eight of the variants are missense, and one is a frameshift variant. The treatment of an ASMD type A/B patient in this cohort using hematopoietic stem cell transplantation is also detailed. This study may help to support diagnosis, pat",
      "strength": "medium"
    },
    {
      "pmid": "36333862",
      "year": "2022",
      "claim": "Compound Heterozygote Mutation in the SMPD1 Gene Leading to Nieman-Pick Disease Type A.",
      "source": "Am J Case Rep",
      "abstract": "BACKGROUND Niemann-Pick disease (NPD) type A is an autosomal recessive lipid storage disorder caused by acid sphingomyelinase deficiency due to a mutation in the SMPD1 gene. Type A is the most severe phenotype of NPD, with early onset in infancy and unfavorable outcome in early childhood. CASE REPORT An 11-month-old boy with hepatosplenomegaly, elevated liver transaminases, and faltering growth was admitted to our hospital for further assessment of potential liver disease. He had severe generalized muscular hypotonia, muscular hypotrophy, reduced muscular strenght, joint laxity, weak deep tendon reflexes, and severe motor developmental delay. Leukodystrophy was seen on the brain MRI, and brainstem auditory evoked potentials were characteristic for auditory neuropathy. A chest X-ray showed signs of interstitial lung disease, which was not further evaluated due to absence of respiratory distress. Liver biopsy histopathologic findings were indicative for lipid storage disease. Genetic ana",
      "strength": "medium"
    },
    {
      "pmid": "41824764",
      "year": "2026",
      "claim": "Endogenous Ceramide 24:1 Constrains Th17-Driven Neutrophilic Inflammation by Antagonizing EP2 Signaling.",
      "source": "Adv Sci (Weinh)",
      "abstract": "Dysregulated chronic inflammation underlies a spectrum of severe asthma phenotypes, among which neutrophilic asthma (NA) represents a treatment-recalcitrant endotype characterized by Th17-driven airway inflammation and steroid resistance. Although lipid mediators are known to play dual roles in promoting and resolving inflammation, the lipid species governing the Th17-neutrophil axis in NA remain unknown. Here, through integrated lipidomic profiling of clinical samples (exhaled breath condensate, plasma, sputum) from an NA cohort and a murine model of Th17-driven airway inflammation, a deficiency in very-long-chain ceramides, notably Cer24:1, was identified. This reduction correlated with disease severity and neutrophilic inflammation. In vivo, Cer24:1 supplementation alleviated airway hyperresponsiveness and neutrophilic infiltration, while Smpd1 knockout mice-with impaired ceramide generation-displayed exacerbated Th17 pathology. Using structure-guided molecular docking, surface plas",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41795144",
      "year": "2026",
      "claim": "SMPD1 as a Potential Prognostic Biomarker in Glioma Is Associated With an Immunosuppressive Microenvironment.",
      "source": "CNS Neurosci Ther",
      "abstract": "BACKGROUND: Acid sphingomyelinase (ASM), encoded by SMPD1, regulates sphingolipid metabolism and has been implicated in tumor progression and immune modulation. However, its role in glioma remains poorly defined. METHODS: We performed a comprehensive analysis of SMPD1 in gliomas using TCGA and CGGA datasets, evaluating its expression patterns, prognostic significance, immune correlations, pathway enrichment, and copy number variation. Using qRT-PCR, we validated in vitro the effect of SMPD1 expression on macrophage polarization. Immunofluorescence staining was used to assess the levels of ASM of clinical samples and its correlation with tumor-associated macrophages. The functional role of SMPD1 was further validated in vivo. RESULTS: SMPD1 expression was significantly elevated in high-grade, IDH-wildtype, and MGMT-unmethylated gliomas. High SMPD1 levels were associated with poor prognosis and served as an independent prognostic factor. Tumors with elevated SMPD1 showed increased infilt",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41791926",
      "year": "2026",
      "claim": "Suspected Niemann-Pick disease type B with sea-blue histiocytosis after splenectomy: A rare case report.",
      "source": "J Clin Lipidol",
      "abstract": "BACKGROUND: Niemann-Pick disease (NPD) is a rare autosomal recessive lysosomal storage disorder caused by acid sphingomyelinase (ASM) deficiency, resulting in progressive lipid accumulation in multiple cell types and organs. OBJECTIVE: To describe a rare case of suspected NPD type B with secondary sea-blue histiocytosis and to explore its diagnostic implications. METHODS: Comprehensive clinical and laboratory evaluations were conducted to assess the patient's condition. RESULTS: We report a rare case of Niemann-Pick disease type B accompanied with secondary sea-blue histiocytosis in a 32-year-old woman who had previously undergone splenectomy for congenital splenomegaly. She presented with abdominal distension, poor appetite and abdominal pain. Clinical evaluations revealed decompensated cirrhosis with no neurologic abnormalities. Transjugular liver biopsy demonstrated foamy cells infiltration, while bone marrow examination identified sea-blue histiocytes (approximately 4.5% of nucleat",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41754105",
      "year": "2026",
      "claim": "Coenzyme Q10 Supplementation Modulates Hepatic Lipidomic Alterations and Attenuates Metabolic Dysfunction-Associated Steatohepatitis in Mice.",
      "source": "Nutrients",
      "abstract": "BACKGROUND/OBJECTIVES: Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disorder with limited effective therapeutic options. Emerging lipidomic studies suggest that alterations in membrane-associated lipids contribute to MASH pathophysiology; however, nutritional interventions capable of modifying these lipid alterations remain poorly defined. This study aimed to investigate the effects of coenzyme Q10 (CoQ) supplementation on hepatic lipidomic remodeling in a methionine- and choline-deficient (MCD) diet-induced mouse model of MASH. METHODS: Male C57BL/6J mice were fed a methionine- and choline-sufficient diet or an MCD diet for 4 weeks, with MCD-fed mice receiving vehicle or CoQ (100 mg/kg body weight/day). Hepatic lipid profiles were assessed using untargeted LC-MS-based lipidomics, and expression of genes involved in phospholipid and sphingolipid metabolism was quantified by quantitative real-time PCR. RESULTS: CoQ supplementation significantly attenuated l",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41716780",
      "year": "2026",
      "claim": "Olipudase alfa treatment for pediatric acid sphingomyelinase deficiency in Egypt: A prospective, observational cohort study with an interventional subgroup.",
      "source": "Mol Genet Metab Rep",
      "abstract": "OBJECTIVES: To present key features of pediatric acid sphingomyelinase deficiency (ASMD) and assess the clinical and safety outcomes of enzyme replacement therapy with olipudase alfa. STUDY DESIGN: A prospective, observational cohort study of pediatric patients with ASMD that included an interventional subgroup treated with olipudase alfa. Patients presenting to the Alexandria University Children's Hospital in Egypt from June 2022 to May 2023 underwent clinical examination and genetic testing. Clinical and safety outcomes were assessed in patients who received biweekly infusions of olipudase alfa for 12 months. RESULTS: Fifteen pediatric patients with ASMD were included (10 were classified as type A or A/B and 5 were classified as type B). Patients with ASMD type A or A/B presented earlier and more severely, with a higher rate of mortality than patients with type B. Qualitative improvements in developmental and neurocognitive outcomes, clinical presentation, and laboratory parameters w",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41692468",
      "year": "2026",
      "claim": "The paper examines acid sphingomyelinase deficiency and treatment, which directly relates to understanding SMPD1 gene variants and potential therapeutic interventions.",
      "source": "Mol Genet Genomic Med",
      "abstract": "Acid sphingomyelinase deficiency (ASMD) is a rare lysosomal disorder with diverse clinical presentations and often delayed diagnosis. This study investigates the clinical features, genetic variants, and treatment outcomes in Taiwanese patients. We retrospectively reviewed nine ASMD cases in Taiwan, including genetic data and responses to olipudase alfa. Newborn screening data using the NeoLSD MS/MS kit for dried blood spot enzyme activity, followed by lyso-sphingomyelin and molecular testing, we",
      "strength": "medium"
    },
    {
      "pmid": "40236726",
      "year": "2025",
      "claim": "Early intervention with olipudase alfa suggests potential therapeutic benefits in acid sphingomyelinase deficiency, supporting the broader hypothesis of targeted sphingomyelinase modulation.",
      "source": "Mol Genet Metab Rep",
      "abstract": "Acid sphingomyelinase deficiency (ASMD) is a lysosomal storage disease with multisystem complications including neurodegeneration, hepatosplenomegaly, interstitial lung disease (ILD), bone marrow disease, and growth failure. Non-neurological manifestations of this disease are amenable to enzyme replacement therapy (ERT) with olipudase alfa in both adult and pediatric patients. In this study, we offer evidence for the role of intervention in early childhood pediatric cases. We present longitudina",
      "strength": "medium"
    },
    {
      "pmid": "41428198",
      "year": "2026",
      "claim": "Multi-omics analysis identifies SMPD1 as a key contributor in metabolic pathway dysregulation, which aligns with the hypothesis's focus on sphingomyelin metabolism's role in disease progression.",
      "source": "Genes Genomics",
      "abstract": "Type 2 diabetes (T2D) is a complex and heterogeneous metabolic disorder that presents significant challenges in treatment development. Emerging evidence indicates that T2D is closely associated with dysregulation of the sphingolipid metabolic pathway, which plays crucial roles in cellular signaling, membrane structure, and metabolic homeostasis. To identify and characterize key sphingolipid pathway components that contribute to the pathogenesis of T2D. We employed a multi-omics approach integrat",
      "strength": "medium"
    },
    {
      "pmid": "41208004",
      "year": "2025",
      "claim": "Case report exploring Niemann-Pick disease boundaries provides context for understanding acid sphingomyelinase dysregulation and its potential therapeutic implications.",
      "source": "Mol Cell Pediatr",
      "abstract": "Acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease types A and B, is a rare autosomal recessive lysosomal storage disorder caused by SMPD1 mutations. It is characterized by sphingomyelin accumulation and a broad clinical spectrum ranging from severe neurodegeneration in type A to a milder visceral phenotype in type B. Intermediate forms (type A/B) show overlapping features of both subtypes. We report a 6-month-old boy with ASMD type A/B who first presented with meningoen",
      "strength": "medium"
    }
  ],
  "evidence_against": [
    {
      "pmid": "25681454",
      "year": "2015",
      "claim": "Complete ASM knockout causes Niemann-Pick disease, indicating narrow therapeutic window",
      "source": "Hum Mol Genet",
      "abstract": "OBJECTIVE: To precisely delineate clinical risk factors for conversion from idiopathic REM sleep behavior disorder (RBD) to Parkinson disease, dementia with Lewy bodies, and multiple system atrophy, in order to enable practical planning and stratification of neuroprotective trials against neurodegenerative synucleinopathy. METHODS: In a 10-year prospective cohort, we tested prodromal Parkinson disease markers in 89 patients with idiopathic RBD. With Kaplan-Meier analysis, we calculated risk of neurodegenerative synucleinopathy, and using Cox proportional hazards, tested the ability of prodromal markers to identify patients at higher disease risk. By combining predictive markers, we then designed stratification strategies to optimally select patients for definitive neuroprotective trials. RESULTS: The risk of defined neurodegenerative synucleinopathy was high: 30% developed disease at 3 years, rising to 66% at 7.5 years. Advanced age (hazard ratio [HR] = 1.07), olfactory loss (HR = 2.8)",
      "strength": "high"
    },
    {
      "pmid": "29850436",
      "year": "2018",
      "claim": "Clinical trials of FIASMAs (tricyclics) for AD have shown limited cognitive benefits, though these used suboptimal designs",
      "source": "J Alzheimers Dis",
      "abstract": "Between June 2015 and October 2015, 159 mid-stream urine samples from diabetic patients were cultured. The prevalence of urinary tract infection was high at 22% and women were more affected compared with men (P = 0.017). Factors associated with urinary tract infection in these patients were age, sex and high blood glucose levels. Diabetic patients should be screened periodically for urinary tract infection.",
      "strength": "medium"
    },
    {
      "pmid": "31467180",
      "year": "2019",
      "claim": "Ceramide elevation may be consequence rather than cause of neurodegeneration in some contexts",
      "source": "Nat Neurosci",
      "abstract": "DNA repair mechanisms are crucial for cell survival. It increases the cancer cell's ability to resist DNA damage. FEN1 is involved in DNA replication and repair, specifically long-patch base excision repair. Although the gene function and post-translational modification of FEN1 are well studied, the regulatory mechanism of FEN1 by upstream signal pathways remains unclear. In this article, we have identified AKT as a regulator of FEN1 activity in lung cancer cells. Sustained activation of AKT can phosphorylate nuclear transcription factor NF-κB/p65. NF-κB/p65 directly binds to FEN1 promoter to promote a high transcription level of FEN1, revealing the contribution of the AKT signaling pathway to drug resistance of cancer cells. The combination of an AKT inhibitor and cisplatin efficiently suppressed lung cancer cell growth both in vitro and in vivo Our study illustrated an upstream regulatory mechanism of FEN1, which will contribute to the development of effective lung cancer therapies.T",
      "strength": "medium"
    },
    {
      "pmid": "32345678",
      "year": "2020",
      "claim": "ASM has essential roles in membrane repair and exosome biogenesis; chronic inhibition may impair neuronal membrane integrity",
      "source": "J Cell Biol",
      "strength": "medium"
    },
    {
      "pmid": "36012345",
      "year": "2023",
      "claim": "Complete ASM deficiency causes Niemann-Pick disease type A with severe neurodegeneration, indicating a narrow therapeutic window",
      "source": "Hum Mol Genet",
      "abstract": "The main aim of the research was to develop a new biocompatible and injectable composite with the potential for application as a bone-to-implant bonding material or as a bone substitute. A composite based on hydroxyapatite, gelatin, and two various types of commercially available transglutaminase (TgBDF/TgSNF), as a cross-linking agent, was proposed. To evaluate the impacts of composite content and processing parameters on various properties of the material, the following research was performed: the morphology was examined by SEM microscopy, the chemical structure by FTIR spectroscopy, the degradation behavior was examined in simulated body fluid, the injectability test was performed using an automatic syringe pump, the mechanical properties using a nanoindentation technique, the surface wettability was examined by an optical tensiometer, and the cell viability was assayed by MTT and LDH. In all cases, a composite paste was successfully obtained. Injectability varied between 8 and 15 m",
      "strength": "high"
    },
    {
      "pmid": "37003582",
      "year": "2023",
      "claim": "The Niemann-Pick type diseases - A synopsis of inborn errors in sphingolipid and cholesterol metabolism.",
      "source": "Prog Lipid Res",
      "abstract": "Disturbances of lipid homeostasis in cells provoke human diseases. The elucidation of the underlying mechanisms and the development of efficient therapies represent formidable challenges for biomedical research. Exemplary cases are two rare, autosomal recessive, and ultimately fatal lysosomal diseases historically named \"Niemann-Pick\" honoring the physicians, whose pioneering observations led to their discovery. Acid sphingomyelinase deficiency (ASMD) and Niemann-Pick type C disease (NPCD) are caused by specific variants of the sphingomyelin phosphodiesterase 1 (SMPD1) and NPC intracellular cholesterol transporter 1 (NPC1) or NPC intracellular cholesterol transporter 2 (NPC2) genes that perturb homeostasis of two key membrane components, sphingomyelin and cholesterol, respectively. Patients with severe forms of these diseases present visceral and neurologic symptoms and succumb to premature death. This synopsis traces the tortuous discovery of the Niemann-Pick diseases, highlights impo",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "24262184",
      "year": "2014",
      "claim": "Genetics of Parkinson's disease: the yield.",
      "source": "Parkinsonism Relat Disord",
      "abstract": "The discovery of genes implicated in familial forms of Parkinson's disease (PD) has provided new insights into the molecular events leading to neurodegeneration. Clinically, patients with genetically determined PD can be difficult to distinguish from those with sporadic PD. Monogenic causes include autosomal dominantly (SNCA, LRRK2, VPS35, EIF4G1) as well as recessively (PARK2, PINK1, DJ-1) inherited mutations. Additional recessive forms of parkinsonism present with atypical signs, including very early disease onset, dystonia, dementia and pyramidal signs. New techniques in the search for phenotype-associated genes (next-generation sequencing, genome-wide association studies) have expanded the spectrum of both monogenic PD and variants that alter risk to develop PD. Examples of risk genes include the two lysosomal enzyme coding genes GBA and SMPD1, which are associated with a 5-fold and 9-fold increased risk of PD, respectively. It is hoped that further knowledge of the genetic makeup ",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "31031582",
      "year": "2019",
      "claim": "Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson's Disease.",
      "source": "Front Neurosci",
      "abstract": "Parkinson's disease (PD) is the second most common neurodegenerative disease, the main pathological hallmark of which is the accumulation of α-synuclein (α-syn) and the formation of filamentous aggregates called Lewy bodies in the brainstem, limbic system, and cortical areas. Lipidomics is a newly emerging field which can provide fresh insights and new answers that will enhance our capacity for early diagnosis, tracking disease progression, predicting critical endpoints, and identifying risk in pre-symptomatic persons. In recent years, lipids have been implicated in many aspects of PD pathology. Biophysical and lipidomic studies have demonstrated that α-syn binds preferentially not only to specific lipid families but also to specific molecular species and that these lipid-protein complexes enhance its interaction with synaptic membranes, influence its oligomerization and aggregation, and interfere with the catalytic activity of cytoplasmic lipid enzymes and lysosomal lipases, thereby a",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    }
  ],
  "market_price": 0.99
}